News und Analysen

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that Sanofi will be transitioning its rights and obligations related to SAR445136, a zinc finger nuclease

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at the 40^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11^th, at 10:30

Premier, Inc. (NASDAQ: PINC) today announced that members of its management team will participate in the 40^th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 11, 2022. The conference is a

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its Lixoft division, a leading

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will provide a corporate presentation at the H.C. Wainwright BIOCONNECT Virtual Conference on

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cell-based virology assays and molecular diagnostic systems, announced today that it will present at the 40^th

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of

Pfizer Inc. (NYSE: PFE) announced that the U.S. government has committed to purchasing an additional 10 million treatment courses of its COVID-19 oral therapy, PAXLOVID™ (nirmatrelvir [PF-07321332]

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and CEO, at the 40^th Annual J.P. Morgan Healthcare Conference on

DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 40^th annual J.P. Morgan Healthcare

Novocure (NASDAQ: NVCR) announced today it will participate in the 40^th Annual J.P. Morgan Virtual Healthcare Conference on January 10 through January 13, 2022. William Doyle, Novocure’s Executive

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright BIOCONNECT

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced the Company has completed the acquisition of CenterPointe Behavioral Health System, the largest dedicated behavioral healthcare

Vancouver Clinic and Humana have teamed up to bring additional access to patient-focused primary care to Gresham, Oregon. Enliven by Vancouver Clinic (Enliven) recently opened its doors for the

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) of a booster dose of the

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and CEO, at the Goldman Sachs 14^th Annual Healthcare CEOs

Respiratory therapists, who are essential to treating COVID-19 patients, top the list of most in-demand temporary allied healthcare professionals, according to a new survey by AMN Healthcare, the

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, issued the following statement from

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, February 8, 2022. The

Quidel Corporation (NASDAQ: QDEL) (“Quidel”) and Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) (“Ortho”) today announced that they have entered into a definitive agreement in which Quidel

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has authorized the emergency use of PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for

Pfizer Inc. (NYSE: PFE) announced an additional agreement with the United Kingdom (UK) government to supply an additional 2.5 million treatment courses of its investigational candidate PAXLOVID™

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a